Despite recent advances in the nanomedicine for treating brain cancer, the prognosis for patients with glioblastoma multiforme remains poor due to the highly invasive nature of the tumors. One major challenge for nanomedicine is to achieve an extensive yet specific distribution at the brain tumor area, especially when targets including diffuse infiltrating cancer cells are distant from the site of administration. Neural stem cells with their inherent tumor-tropic migratory capability, may offer a novel approach for targeted delivery of nanomedicine to distant and diffuse tumor sites. Here, we demonstrate a proof-of-concept study on the combination of neural stem cell and silica nanoparticle-doxorubicin conjugates with the pH mediated drug release for glioma therapy. Our results show that an FDA approved neural stem cell line HB1.F3.CD can efficiently take up the conjugates and maintain the homing ability to the glioma cells in vitro. In vivo studies indicate the neural stem cells can targeted deliver the nanomedicine to the tumor area and enhance the therapeutic outcome in the context of glioma.
Date:
2013-09-08
Relation:
Abstracts of Papers - American Chemical Society. 2013 Sep 8;246:191-COLL.
